Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

Roche announced one-year Phase III data from MEERKAT and SANDCAT studies showing vamikibart, an anti-IL-6 monoclonal antibody, demonstrated sustained vision improvements and macular thickness reductions in uveitic macular edema patients. The FDA has accepted Roche's Biologics License Application with an approval decision expected by July 2027. If approved, vamikibart would be the first non-steroid targeted treatment for UME, potentially establishing a new standard of care.